The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications

PharmacoEconomics

Volumn 35, Issue 12, 2017, Pages 1271-1285

  Ferrario, Alessandra ^a   Arāja, Diāna ^b   Bochenek, Tomasz ^c   Čatić, Tarik ^d   Dankó, Dávid ^e   Dimitrova, Maria ^f   Fürst, Jurij ^g   Greičiūtė Kuprijanov, Ieva ^h   Hoxha, Iris ⁱ   Jakupi, Arianit ^j   Laidmäe, Erki ^k   Löblová, Olga ^l   Mardare, Ileana ^m   Markovic Pekovic, Vanda ^n,o   Meshkov, Dmitry ^p   Novakovic, Tanja ^q   Petrova, Guenka ^f   Pomorski, Maciej ^r   Tomek, Dominik ^s   Voncina, Luka ^t   Haycox, Alan ^u   Kanavos, Panos ^a   Vella Bonanno, Patricia ^v   Godman, Brian ^u,v,w   more..

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d Society for Pharmacoeconomics and Outcomes Research in Bosnia and Herzegovina ISPOR BH   (Bosnia and Herzegovina)

^e Institute of Data Analytics and Information Systems   (Hungary)

^f MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^g Health Insurance Institute of Slovenia   (Slovenia)

^h Ministry of Health of the Republic of Lithuania   (Lithuania)

ⁱ Maastricht University   (Albania)

^j Independent Consultant ^*  (Serbia)

^k Estonian Health Insurance Fund   (Estonia)

^l CENTRAL EUROPEAN UNIVERSITY   (Hungary)

^m CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁿ MINISTRY OF HEALTH AND SOCIAL WELFARE   (Bosnia and Herzegovina)

^o UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^p N A SEMASHKO NATIONAL RESEARCH INSTITUTE OF PUBLIC HEALTH   (Russian Federation)

^q Pediatric Association of Serbia   (Serbia)

^r Agency for Health Technology Assessment in Poland   (Poland)

^s SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^t Independent Consultant   (Croatia)

^u UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^v UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^w KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; DRUG;

ARTICLE; BUDGET; BULGARIA; COST EFFECTIVENESS ANALYSIS; ESTONIA; EUROPE; HUMAN; HUNGARY; LATVIA; LITHUANIA; MEDICAL INFORMATION SYSTEM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REIMBURSEMENT; RISK MANAGEMENT; ROMANIA; SERBIA; SLOVENIA; DRUG INDUSTRY; EASTERN EUROPE; ECONOMICS; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PHARMACOECONOMICS; QUESTIONNAIRE;

DELIVERY OF HEALTH CARE; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EUROPE; EUROPE, EASTERN; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACEUTICAL PREPARATIONS; SURVEYS AND QUESTIONNAIRES;

EID: 85028005939     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-017-0559-4     Document Type: Article

References (49)

1. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2014;124:39–47.
2. Howard DHBP, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–62.
3. WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1. Accessed 22 Feb 2017.
4. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between health care payers and manufacturers. Health Policy. 2010;96(3):179–90.
5. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels, Belgium: EMiNet. 2013. http://eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario%2C%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf. Accessed 22 Feb 2017.
6. Garrison LJ, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr P, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–19.
7. Hollis A. Sustainable financing of innovative therapies: a review of approaches. PharmacoEconomics. 2016;34(10):971–80.
8. Carlson J, Chen S, Garrison LP Jr. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0535-z.
9. Lu C, Lupton C, Rakowsky S, Babar Z, Ross-Degnan D, Wagner A. Patient access schemes in Asia-pacific markets: current experience and future potential. J Pharm Policy Pract. 2015;8(1):6.
10. Jarosławski S, Toumi M. Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence. Appl Health Econ Health Policy. 2011;9(4):209–15.
11. Jaroslawski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res. 2011;11(1):259.
12. Towse A, Garrison LP. Can’t get no satisfaction? Will pay for performance help? toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 2010;28(2):93–102.
13. Garrison LJ, Carlson J, Bajaj P, Towse A, Neumann P, Sullivan S, et al. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care. 2015;21(9):632–40.
14. Garrison LP, Towse A. Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Value Health. 2009;12(7):A488.
15. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
16. Klemp M, Frønsdal KB, Facey K. What principles should govern the use of managed entry agreements?. Int J Technol Assess Health Care. 2017;27(1):77–83. doi:10.1017/S0266462310001297.
17. Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed entry agreements for oncology drugs: lessons from the european experience to inform the future. Front Pharmacol. 2017;8(171):1–8.
18. Garattini L, Casadei G. Risk sharing agreements: What lessons from Italy? Int J Technol Assess Health Care. 2011;27(2):169–72.
19. Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16(1):1–3.
20. Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, et al. Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure. Value Health. 2015;18(1):131–6.
21. Simon S, Clopes A, Gasol-Boncompte M, Cajal R, Segu J, Crespo R, et al. Evaluation of a payment by result scheme in a Catalan cancer centre: Gefitinib in EGFR mutation-positive advanced non-small cell lung cancer. Value Health. 2015;18(7):A492.
22. Garattini L, Curto A. Performance-based agreements in Italy: ‘Trendy Outcomes’ or mere illusions? PharmacoEconomics. 2016;34(10):967–9.
23. Araja D, Kolves K. Managed entry agreements for new medicines in the Baltic countries. EuroHealth. 2016;22(1):27–30.
24. Kwong D, Ferrario A, Adamski J, Inotai A, Kalo Z. Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland. EuroHealth. 2014;20(2):25–8.
25. Matusewicz W, Godman B, Pedersen HB, Furst J, Gulbinovic J, Mack A, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–8.
26. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
27. Kostic M, Djakovic L, Sujic R, Godman B, Jankovic SM. Inflammatory bowel diseases (Crohn s Disease and Ulcerative Colitis): cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017;15(1):85–93.
28. Piperska. 2017. http://www.piperska.org/. Accessed 22 Feb 2017.
29. Godman B, Paterson K, Malmstrom RE, Selke G, Fagot JP, Mrak J. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439–41.
30. Department of Health Insurance of the Federation of Bosnia and Herzegovina, list of decisions on medicines. http://www.fedzzo.com.ba/bs/dokument/odluka-o-listi-lijekova/215. Accessed 17 Aug 2017.
31. IMS Institute. Global oncology trend report. A review of 2015 and outlook to 2020. 2016. http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/global-oncology-trend-report-a-review-of-2015-and-outlook-to-2020#. Accessed 22 Feb 2017.
32. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996–1000.
33. Bennette C, Richards C, Sullivan S, Ramsey S. Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff. 2016;35(5):805–12.
34. Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
35. Montgomery B. Review of access to new medicines independent review by Dr Brian montgomery. Edinburgh: The Scottish Government. 2016. http://www.gov.scot/Resource/0051/00511595.pdf. Accessed 22 Feb 2017.
36. NHS England. Cancer drugs fund. 2017. https://www.england.nhs.uk/cancer/cdf/. Accessed 22 Feb 2017.
37. Scottish Medicines Consortium. Patient and clinician engagement. 2017. https://www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/Patient_and_Clinician_Engagement_Factsheet. Accessed 22 Feb 2017.
38. NICE. Appraising life-extending, end of life treatments. Supplementary advice to the Appraisal Committees. London. 2009. https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2. Accessed 22 Feb 2017.
39. Haycox A. Why Cancer? PharmacoEconomics. 2016;34(7):625–7.
40. Černěnko M, Dančíková Z, Friedmanová M, Harvan P, Kišš Š, Laktišová M, et al. Revízia Výdavkov Na Zdravotníctvo. Záverečná Správa. Ministervo financií SR, Ministerstvo zdravotníctva SR. 2016.
41. Piško M. Drahá Liečba Závisí Aj Od Sily Hlasiviek. 2016.
42. Barros PP. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ. 2011;20(4):461–70.
43. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2008;26(7):551–6.
44. Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law. 2011;6(3):391–403.
45. Lilico A. Risk sharing pricing models in the distribution of pharmaceuticals. London: Europe Economics. 2003. http://www.europe-economics.com/publications/risk_sharing_al.pdf. Accessed 22 Feb 2017.
46. Barros P, Levaggi R. Searching for approval: risk sharing as price discount? Mimeo; 2013. https://www.gate.cnrs.fr/IMG/pdf/EHEW_2013_Levaggi.pdf. Accessed 2 Mar 2017.
47. Zaric GS, O’Brien BJ. Analysis of a pharmaceutical risk sharing agreement based on the purchaser’s total budget. Health Econ. 2005;14(8):793–803.
48. Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value Health. 2009;12(5):838–45.
49. Croatian Health Insurance Fund, Pravilnik o mjerilima za stavljanje lijekova na osnovnu i dopunsku listu. http://www.hzzo.hr/zdravstveni-sustav-rh/pravilnik-o-mjerilima-za-stavljanje-lijekova-na-osnovnu-i-dopunsku-listu. Accessed 11 Aug 2017.